Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CMLSusan Branford, Timothy P. Hughes, Brad Sullivan et al.|Blood|2013Cited by 177
Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and CyclosporinDavid J. Curtis, Geoffrey R. Hill, Sushrut Patil et al.|New England Journal of Medicine|2025Cited by 52
TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapyEva Nievergall, Deborah L. White, John Reynolds et al.|Leukemia|2016Cited by 50
Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinibChung Hoow Kok, Timothy P. Hughes, David T Yeung et al.|Blood Advances|2019Cited by 43
Restricted cell cycle is essential for clonal evolution and therapeutic resistance of pre-leukemic stem cellsCédric S. Tremblay, David J. Curtis, Jesslyn Saw et al.|Nature Communications|2018Cited by 19